Next-generation vascular prosthetics
Cutting-edge biomaterials leverage the regenerative potential of the human body
Our Mission
For over 60 years the vascular graft space has been dominated by two materials - polyethylene terephthalate (PET) and expanded poly(tetrafluoroethylene) (ePTFE). Although these materials have saved countless lives, they do not integrate well with host tissue and remain in the patient’s body for the remainder of their lives. By leveraging decades of tissue-engineering research, we have re-designed vascular graft materials from first principles to create vascular prosthetics that match the mechanics of our vascular system, and transform over time into fully autologous conduits. Our first product, the deNovo1 AVG will mark the first step on our path towards pushing inferior materials out of the clinic.
Our Science
The foundational technology behind our grafts at Anova biomedical, Inc. comes from the pioneering work by Professor Yadong Wang at Cornell University. For the last twenty years, Professor Wang has evolved his biodegradable elastomer platform to create materials that are optimized for vascular engineering.
Our Technology
-
Biodegradable Elastomers
Our proprietary biomaterials produce vascular prosthetics that lead to the generation of a fully autologous elastic neo-artery.
-
Advanced Manufacturing
Our novel manufacturing approach provides unprecedented control during microfiber deposition to produce prosthetics that mimic the structure and mechanics of native arteries.
-
Easy Clinical Adoption
All of our devices are made with careful consideration of advice from our clinical advisors. As a result, our products can be easily integrated into clinical workflows with no special considerations for shipping, storage, or implantation.
Meet the Team
-
Anthony D'Amato, PhD
CEO & Co-Founder
-
Yadong Wang, PhD
Chair of Scientific Advisory Board & Co-Founder
-
Nathaniel Wright, PhD
Biomedical Engineer
News and Events
-
![]()
2024 FuzeHub Manufacturing Grant
July, 2024
A collaboration between Anova Biomedical and Cornell University was awarded a Manufacturing Grant from FuzeHub. This award will fund efforts to scale production of our novel materials and vascular grafts.
-
![]()
NSF Phase I SBIR Award
August, 2024
Anova Biomedical was awarded a Phase I SBIR grant through the National Science Foundation (NSF). This $275,000 award funds a 1 year long project focused on our novel 3D printing resin that is being developed to produce personalized vascular prosthetics.
-
![]()
Center for Life Science Ventures Admission
September, 2024
Anova Biomedical was recently admitted to the Cornell Center for Life Sciences Venture (CLSV). CLSV is a residential startup incubator on Cornell's campus in Ithaca, NY that is funded through the Cornell Office of the Vice President for Research & Innovation, the Cornell Institute of Biotechnology, and NYSTAR.
Contact
To learn more about Anova Biomedical, please fill out the information below and our team will follow up with you as soon as possible.